GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pacific Biosciences of California Inc (NAS:PACB) » Definitions » Cash And Cash Equivalents

Pacific Biosciences of California (Pacific Biosciences of California) Cash And Cash Equivalents

: $179.9 Mil (As of Dec. 2023)
View and export this data going back to 2010. Start your Free Trial

Pacific Biosciences of California's quarterly cash and cash equivalents increased from Jun. 2023 ($209.29 Mil) to Sep. 2023 ($385.65 Mil) but then stayed the same from Sep. 2023 ($385.65 Mil) to Dec. 2023 ($179.91 Mil).

Pacific Biosciences of California's annual cash and cash equivalents declined from Dec. 2021 ($460.73 Mil) to Dec. 2022 ($325.09 Mil) and declined from Dec. 2022 ($325.09 Mil) to Dec. 2023 ($179.91 Mil).


Pacific Biosciences of California Cash And Cash Equivalents Historical Data

The historical data trend for Pacific Biosciences of California's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacific Biosciences of California Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.63 81.61 460.73 325.09 179.91

Pacific Biosciences of California Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash And Cash Equivalents Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 325.09 353.83 209.29 385.65 179.91

Pacific Biosciences of California Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Pacific Biosciences of California  (NAS:PACB) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Pacific Biosciences of California Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Pacific Biosciences of California's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Pacific Biosciences of California (Pacific Biosciences of California) Business Description

Traded in Other Exchanges
Address
1305 O’Brien Drive, Menlo Park, CA, USA, 94025
Pacific Biosciences of California Inc is a biotechnology company focused on the design, development, and commercialization of tools for biological research. The company develops sequencing systems to assist in resolving genetically complex problems. Its sequencing systems provide access to a wide range of applications and are designed for expandable improvements to performance capability. The majority of the company's revenue is derived from North America, followed by Asia and Europe.
Executives
Oene Mark Van officer: Chief Operating Officer 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Christian O Henry director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
David W Meline director 3M COMPANY, 3M OFFICE OF GENERAL COUNSEL, ST PAUL MN 55144-1000
Susan G. Kim officer: Chief Financial Officer 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Jeff Eidel officer: See Remarks 1305 O'BRIEN DR., MENLO PARK CA 94025
Michele Farmer officer: Chief Accounting Officer 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
William W. Ericson director 777 MARINERS ISLAND BOULEVARD, SUITE 550, SAN MATEO CA 94404
Peter Fromen officer: Chief Commercial Officer 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Hannah Valantine director 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Michael Hunkapiller director 400 HAMILTON AVENUE, 4TH FLOOR, PALO ALTO CA 94301
Eric Schaefer officer: VP Chief Accounting Officer 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Kathy Ordonez director 3 GIRALDA FARMS, C/O QUEST DIAGNOSTICS, MADISON NJ 07940
Randall S Livingston director
Lucy Shapiro director 10210 GENETIC CENTER COURT, SAN DIEGO CA 92121
David Botstein director 1380 WILLOW ROAD, PACIFIC BIOSCIENCES OF CALIFORNIA INC, MENLO PARK CA 94025